EIF6 and cutaneous melanoma: In eIF6 over-expression specimens, the survival rates of brain lower-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), pancreatic adenocarcinoma (PAAD), and skin cutaneous melanoma (SKCM) were all significantly reduced (Figure 1A).